Literature DB >> 901741

Serum concentrations of lithium after three proprietary preparations of lithium carbonate (Priadel, Phasal and Camcolit).

E H Bennie, A K Manzoor, A M Scott, G S Fell.   

Abstract

1 The serum lithium concentration was measured before dosing, and at 2, 4, 6, 8, 10, 20, 22, and 24 h after three proprietary preparations of lithium carbonate (Camcolit, Phasal or Priadel). 2 A total of twenty-eight studies were performed on eleven patients. In seven studies the patients received Camcolit, in ten studies patients received Priadel and in eleven the patients took Phasal. 3 The dose of each preparation was adjusted during a 10 week run-in period to maintain the serum lithium within the normal therapeutic range (0.6-1.2 mmol/1). Five patients received one lithium preparation, one patient received three lithium preparations and five patients received four lithium preparations consecutively. 4 After a single daily dose of Phasal and Priadel, the serum lithium remained within the therapeutic range for 24 h. 5 After a single daily dose of Camcolit, the serum lithium remained within the therapeutic range for only 12 h. 6 After three doses of Camcolit (given at 0.800 h, 12.00 h, and 18.00 h) each day, the serum lithium was maintained in the therapeutic range for 24 h.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 901741      PMCID: PMC1429041          DOI: 10.1111/j.1365-2125.1977.tb00766.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Blood levels and management of lithium treatment.

Authors:  J L Crammer; R M Rosser; G Crane
Journal:  Br Med J       Date:  1974-09-14

2.  Prophylactic lithium in recurrent affective disorders.

Authors:  R P Hullin; R McDonald; M N Allsopp
Journal:  Lancet       Date:  1972-05-13       Impact factor: 79.321

3.  Prophylactic lithium in affective disorders. Controlled trial.

Authors:  A Coppen; R Noguera; J Bailey; B H Burns; M S Swani; E H Hare; R Gardner; R Maggs
Journal:  Lancet       Date:  1971-08-07       Impact factor: 79.321

4.  Value of plasma-lithium monitoring.

Authors:  D E Fry; V Marks
Journal:  Lancet       Date:  1971-05-01       Impact factor: 79.321

5.  Lithium prophylaxis in recurrent affective disorders.

Authors:  J Angst; P Weis; P Grof; P C Baastrup; M Schou
Journal:  Br J Psychiatry       Date:  1970-06       Impact factor: 9.319

6.  Lithium absorption from sustained-release tablets (Duretter).

Authors:  A Amdisen; J Sjögren
Journal:  Acta Pharm Suec       Date:  1968-11

7.  Slow-release lithium carbonate.

Authors:  A Coppen; J E Bailey; S G White
Journal:  J Clin Pharmacol J New Drugs       Date:  1969 May-Jun
  7 in total
  1 in total

1.  Steady-state pharmacokinetics of lithium carbonate in healthy subjects.

Authors:  R Hunter
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.